N-(2-溴-6-甲基苯基)乙酰胺 | 116436-11-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: N-(2-溴-6-甲基苯基)乙酰胺
• 英文名称: N-(2-bromo-6-methylphenyl)acetamide
• CAS: 116436-11-4
• 化学式: C₉H₁₀BrNO
• 分子量: 228.088
• InChiKey: VXIIBTQSQWEMHV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  29.1
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  N-(2-溴-6-甲基苯基)乙酰胺 在 tris-(dibenzylideneacetone)dipalladium(0) 、 potassium phosphate monohydrate 、 bis(2',6'-diisopropoxybiphenyl)cyclohexylphosphine 、 水 、 lithium hydroxide 作用下， 以 乙醇 、 叔丁醇 为溶剂， 反应 2.08h， 生成
  参考文献：
  名称：

  Optimization of Potent Inhibitors of P. falciparum Dihydroorotate Dehydrogenase for the Treatment of Malaria

  摘要：

  Inhibition of dihydroorotate dehydrogenase (DHODH) for P. falciparum potentially represents a new treatment option for malaria, since DHODH catalyzes the rate-limiting step in the pyrimidine biosynthetic pathway and P. falciparum is unable to salvage pyrimidines and must rely on de novo biosynthesis for survival. We report herein the synthesis and structure-activity relationship of a series of 5-(2-methylbenzimidazol-1-yl)-N-alkylthiophene-2-carboxamides that are potent inhibitors against PfDHODH but do not inhibit the human enzyme. On the basis of efficacy observed in three mouse models of malaria, acceptable safety pharmacology risk assessment and safety toxicology profile in rodents, lack of potential drug-drug interactions, acceptable ADME/pharmacokinetic profile, and projected human dose, 5-(4-cyano-2-methyl-1H-benzo[d]imidazol-1-yl)-N-cyclopropylthiophene-2-carboxamide 2q was identified as a potential drug development candidate.

  DOI：

  10.1021/ml200143c
• 作为产物：
  描述：

  3-溴-2-硝基甲苯 在 盐酸 、 溶剂黄146 、 tin(ll) chloride 作用下， 生成 N-(2-溴-6-甲基苯基)乙酰胺
  参考文献：
  名称：

  Burton; Hammond; Kenner, Journal of the Chemical Society, 1926, p. 1803

  摘要：

  DOI：

文献信息

• [EN] MORPHOLINE AND 1,4-OXAZEPANE AMIDES AS SOMATOSTATIN RECEPTOR SUBTYPE 4 (SSTR4) AGONISTS<br/>[FR] AMIDES DE MORPHOLINE ET DE 1,4-OXAZÉPANE UTILISÉS EN TANT QU'AGONISTES DU SOUS-TYPE 4 DU RÉCEPTEUR DE LA SOMATOSTATINE (SSTR4)
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2016075240A1

  公开（公告）日：2016-05-19

  The invention relates to morpholine and 1,4-oxazepane amide derivatives of general formula (I), which are agonists of somatostatin receptor subtype 4 (SSTR4), useful for preventing or treating medical disorders related to SSTR4. In addition, the invention relates to processes for preparing pharmaceutical compositions as well as processes for manufacture of the compounds according to the invention.

  这项发明涉及一般式(I)的吗啡啶和1,4-噁唑烷酮酰胺衍生物，它们是生长抑素受体亚型4（SSTR4）的激动剂，用于预防或治疗与SSTR4相关的医学疾病。此外，该发明涉及制备药物组合物的方法，以及根据该发明制造化合物的方法。
• [EN] PYRROLOPYRIMIDINE ALKYNYL COMPOUNDS AND METHODS OF MAKING AND USING SAME<br/>[FR] COMPOSÉS D'ALCYNYLE DE PYRROLOPYRIMIDINE ET LEURS PROCÉDÉS DE PRÉPARATION ET D'UTILISATION
  申请人：TARGEGEN INC

  公开号：WO2009055674A1

  公开（公告）日：2009-04-30

  Provided herein are pyrrolopyrimide alkynyl compounds, and methods of making and using the same. Such compounds may be used in inflammatory or myeloproliferative disorders. The disclosure also provides for treating cancer.

  本发明提供了吡咯并嘧啶炔基化合物及其制备和使用方法。此类化合物可用于治疗炎症或骨髓增生性疾病。本发明还提供了治疗癌症的方法。
• Rhodium‐Catalyzed <i>ortho</i> ‐Bromination of O‐Phenyl Carbamates Accelerated by a Secondary Amide‐Pendant Cyclopentadienyl Ligand
  作者：Jin Tanaka、Yu Shibata、Anton Joseph、Juntaro Nogami、Jyunichi Terasawa、Ryo Yoshimura、Ken Tanaka

  DOI：10.1002/chem.202000253

  日期：2020.5.7

  RhIII ] complex, bearing an acidic secondary amide moiety on the Cp ring, is able to catalyze the ortho-bromination of O-phenyl carbamates with N-bromosuccinimide (NBS) at room temperature. The presence of the acidic secondary amide moiety on the CpA ligand accelerates the bromination by the hydrogen bond between the acidic NH group of the CpA ligand and the carbonyl group of NBS.

  已经确定，新开发的环戊二烯基铑（III）[CpA RhIII]配合物在Cp环上带有酸性仲酰胺部分，能够与N-溴代琥珀酰亚胺（NBS）催化邻氨基苯甲酸酯的邻溴化反应。在室温下。CpA配体上酸性仲酰胺部分的存在通过CpA配体的酸性NH基团和NBS的羰基之间的氢键加速了溴化反应。
• Pd‐Catalyzed Carbonylative Synthesis of 4 <i>H</i> ‐Benzo[ <i>d</i> ][1,3]Oxazin‐4‐Ones Using Benzene‐1,3,5‐Triyl Triformate as the CO Source
  作者：Yan Zheng、Mengke Dong、Erdong Qu、Jin Bai、Xiao‐Feng Wu、Wanfang Li

  DOI：10.1002/chem.202103137

  日期：2021.11.22

  A Pd-catalyzed CO-free carbonylative synthesis of 4H-benzo[d][1,3]oxazin-4-one derivatives was developed. This new method employed readily available N-(o-bromoaryl)amides as the starting materials and inexpensive benzene-1,3,5-triyl triformate (TFBen) as the stable solid CO surrogate, which would not cause hydrodehalogenation of the starting materials. Remarkably, this method featured a very broad

  开发了 Pd 催化的 4 H -benzo[ d ][1,3]oxazin-4-one 衍生物的无 CO 羰基化合成。这种新方法使用容易获得的N -（邻溴芳基）酰胺作为起始原料，使用廉价的三甲酸苯-1,3,5-三酯（TFBen）作为稳定的固体 CO 替代物，不会引起起始原料的加氢脱卤。值得注意的是，该方法具有非常广泛的底物范围，特别适用于将苯并[ d ][1,3]oxazin-4-one结构引入药物和天然生物活性化合物中。
• Mild CH Halogenation of Anilides and the Isolation of an Unusual Palladium(I)-Palladium(II) Species
  作者：Robin B. Bedford、Mairi F. Haddow、Charlotte J. Mitchell、Ruth L. Webster

  DOI：10.1002/anie.201101606

  日期：2011.6.6

  Reducing the load: A facile palladium‐catalyzed ortho‐selective bromination and chlorination of anilides occurs under aerobic conditions at room temperature when N‐halosuccinimides (NXS) are used in the presence of p‐toluenesulfonic acid (PTSA). The orthopalladated PTSA complex is not only catalytically competent but also undergoes a reductive process to yield an unusual PdI–PdII tetramer (see structure;

  减少负荷：在有氧条件下，在对甲苯磺酸（PTSA）的存在下使用N-卤代琥珀酰亚胺（NXS）时，在室温下好氧条件下，钯的催化邻位溴化和氯离子氯化很容易进行。正统的PTSA配合物不仅具有催化能力，而且还经过还原过程生成不寻常的Pd I –Pd II四聚体（见结构； Pd绿色，O红色，S黄色和C灰色）。